Market Place
Sourcing Support
Ablynx NV`s Cablivi (caplacizumab) Receives Suppl Approval in the U.S.
11 Apr 2024 //
FDA
Cablivi`s Biologic Ablynx (Caplacizumab) Receives Approval in the U.S.
23 Feb 2022 //
FDA
NICE green light for Cablivi in rare blood-clotting disorder
13 Nov 2020 //
PHARMATIMES
NICE rejects Sanofi`s Cablivi in draft guidelines
13 Jun 2020 //
PHARMATIMES
Cablivi® approved by Health Canada for adults living with acquired (aTTP)
02 Mar 2020 //
NEWSWIRE
Innovative treatment Cablivi (caplacizumab-yhdp) granted new technology payment
10 Oct 2019 //
PRESS
Zeldin joins Immunovant as CMO months after Acceleron split
14 Aug 2019 //
FIERCE BIOTECH
Sanofi blood disorder drug wins FDA approval
07 Feb 2019 //
REUTERS
Ablynx`s Cablivi (Caplacizumab) Receives Supplemental Approval in US
06 Feb 2019 //
FDA
FDA approves first therapy for adult patients with rare blood clotting disorder
06 Feb 2019 //
PR NEWSWIRE
Cablivi gets positive results for rare blood clotting disorder
14 Jan 2019 //
PHARMA TIMES
NEJM publishes positive results of trial of Cablivi for rare disorder
10 Jan 2019 //
GLOBENEWSWIRE
With radiotherapy en vogue, Belgian startup nabs nearly $42M in Series A
16 Nov 2018 //
ENDPTS
Ablynx NV`s Cablivi (caplacizumab) Receives Approval in Europe
12 Sep 2018 //
EMA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.